Back to search results

PhD Studentship: Developing novel chemical tools for the treatment of castration resistant prostate cancer

University of Surrey

Qualification Type: PhD
Location: Guildford
Funding for: UK Students, EU Students
Funding amount: £14,777 tax-free yearly stipend
Hours: Full Time
Placed On: 1st November 2018
Closes: 11th January 2019
 

PhD Studentship Faculty of Health and Medical Sciences, University of Surrey, UK

Closing date: 11 January 2019

Start of Studentship: October, 2019

Dr. Mohammad Asim’s laboratory in the Department of Clinical and Experimental Medicine of the University of Surrey is offering PhD studentship to start from October 2019. This is 3-year, fully-funded post and covers the tuition fee for EU/UK students, and offer a tax-free yearly stipend of approx. £14,777. Please talk to the lab head Dr Asim to know more details of the project

Apply link: https://www.surrey.ac.uk/fees-and-funding/studentships/doctoral-college-studentship-award-2019-entry

The project is available in Dr Mohammad Asim’s Prostate Cancer Laboratory who leads the section of Oncology (see https://scholar.google.com/citations?hl=en&user=SE4TLYEAAAAJ&view_op=list_works&sortby=pubdate)

The research will be done in collaboration with the University of Cambridge and Oxford, where Dr Asim holds honorary scientist posts. The outline of the project is as below:

PROJECT DESCRIPTION

Prostate cancer (PrCa) is a leading cause of cancer related male mortality in the United Kingdom with over 10,000 deaths each year. The growth and progression of PrCa is regulated by androgens, which manifest their action by activating the androgen receptor (AR), a ligand activated transcription factor that in turn regulates the growth of PrCa. Since AR signaling is upregulated in PrCa, it is an attractive drug target in the treatment of the advanced PrCa. Hence, widely used androgen deprivation therapy (ADT) is the mainstay treatment for PrCa, which is achieved by the use of anti-androgenic drugs such as Bicalutamide and Enzalutamide. ADT is initially effective but relapse is common leading to castration resistant prostate cancer (CRPC) for which there are no curative treatments. The key question is why does ADT fail and how can we develop more effective anti-androgens to target the AR? In collaboration with the Department of Chemistry University of Cambridge and Nuffield Department of Surgical Sciences, University of Oxford, this project will discover novel anti-androgens to develop curative treatment for CRPC. The findings of this study will pave the way to effectively treat CRPC in order to alleviate the disease burden.

Lab website: https://www.surrey.ac.uk/people/mohammad-asim

FUNDING NOTES

Eligibility: You must have, or expect to achieve, at least a 2:1 honours degree or international equivalent. Students with a lower first degree and a MSc will also be considered. If English is not your first language, you must have IELTS 7 with at least 6.5 in all the components. 

How to apply: Please email m.asim@surrey.ac.uk for more details and advice of completing the studentship form before applying through the University’s Doctoral College to discuss the project

   
We value your feedback on the quality of our adverts. If you have a comment to make about the overall quality of this advert, or its categorisation then please send us your feedback
Advert information

Type / Role:

Subject Area(s):

Location(s):

PhD tools
 
 
 
 
More PhDs from University of Surrey

Show all PhDs for this organisation …

More PhDs like this
Join in and follow us

Browser Upgrade Recommended

jobs.ac.uk has been optimised for the latest browsers.

For the best user experience, we recommend viewing jobs.ac.uk on one of the following:

Google Chrome Firefox Microsoft Edge